Cargando…
Bortezomib therapy-related lung disease in Japanese patients with multiple myeloma: Incidence, mortality and clinical characterization
Because of the potentially high mortality rate (6.5%) associated with bortezomib-induced lung disease (BILD) in Japanese patients with relapsed or refractory multiple myeloma, we evaluated the incidence, mortality and clinical features of BILD in a Japanese population. This study was conducted under...
Autores principales: | Yoshizawa, Kazutake, Mukai, Harumi Y, Miyazawa, Michiko, Miyao, Makiko, Ogawa, Yoshimasa, Ohyashiki, Kazuma, Katoh, Takao, Kusumoto, Masahiko, Gemma, Akihiko, Sakai, Fumikazu, Sugiyama, Yukihiko, Hatake, Kiyohiko, Fukuda, Yuh, Kudoh, Shoji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317820/ https://www.ncbi.nlm.nih.gov/pubmed/24329927 http://dx.doi.org/10.1111/cas.12335 |
Ejemplares similares
-
A network biology approach evaluating the anticancer effects of bortezomib identifies SPARC as a therapeutic target in adult T-cell leukemia cells
por: Ohyashiki, Junko H, et al.
Publicado: (2008) -
Induction of heme oxygenase-1 by cobalt protoporphyrin enhances the antitumour effect of bortezomib in adult T-cell leukaemia cells
por: Hamamura, R S, et al.
Publicado: (2007) -
Incidence and Clinical Features of Drug-induced Lung Injury in Patients with Advanced Colorectal Cancer Receiving Cetuximab: Results of a Prospective Multicenter Registry
por: Satoh, Taroh, et al.
Publicado: (2014) -
Clinical Impact of Down-Regulated Plasma miR-92a Levels in Non-Hodgkin's Lymphoma
por: Ohyashiki, Kazuma, et al.
Publicado: (2011) -
A novel approach to detect KRAS/BRAF mutation for colon cancer: Highly sensitive simultaneous detection of mutations and simple pre-treatment without DNA extraction
por: SUZUKI, SHUN-ICHI, et al.
Publicado: (2015)